Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative neoplasms (MPN) associated with ABL1-ETV6 fusions are rare and poorly characterized.
|
30553471 |
2018 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Notwithstanding two previous reports of ETV6-LYN fusion in myeloproliferative neoplasms (MPN), we report the first case of this fusion in AML and hence broaden its disease association.
|
29153093 |
2017 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
There is no systematic screening of myeloproliferative neoplasms; however, the number of ETV6-ABL1-positive cases and the relative incidence of acute lymphoblastic leukemia and myeloproliferative neoplasms suggest that in adulthood ETV6-ABL1 is more common in BCR-ABL1-negative chronic myeloid leukemia-like myeloproliferations than in acute lymphoblastic leukemia.
|
27229714 |
2016 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of serum from TEL-Syk mice reveals an inflammatory cytokine signature reminiscent of that found in the sera from patients and mouse models of myeloproliferative neoplasms.
|
24116232 |
2013 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors.
|
19394693 |
2009 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPNs) include BCR-ABL in chronic myelogenous leukemia (CML) and a spectrum of PDGFRA/B mutant proteins that are products of intra- (eg, FIP1L1-PDGFRA) or interchromosomal (eg, ETV6-PDGFRB) gene fusions.
|
19147089 |
2009 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Cytogenetic abnormalities of chromosome 12p involving the TEL/ETV6 gene are observed in a variety of hematopoietic neoplasms including acute leukemias, myelodysplastic syndromes, and myeloproliferative disorders.
|
18992913 |
2009 |
Myeloproliferative disease
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Myeloproliferative disorders (MPD) are stem cell-derived clonal diseases arising as a consequence of acquired aberrations in c-ABL, Janus-activated kinase 2 (JAK2), and platelet-derived growth factor receptor (PDGFR) that generate oncogenic fusion tyrosine kinases (FTK), including BCR/ABL, TEL/ABL, TEL/JAK2, and TEL/PDGFbetaR.
|
18757400 |
2008 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We report here that FLT3 may contribute to leukemogenesis in a patient with myeloproliferative disorder and a t(12;13)(p13;q12) translocation through generating a fusion gene with the ETS variant gene 6 (ETV6) gene.
|
16761019 |
2006 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, AMN107 can inhibit myeloid proliferation driven by TEL-PDGFRbeta and FIP1L1-PDGFRalpha and may be a useful drug for treatment of patients with myeloproliferative disease who harbor these kinase fusions.
|
16030188 |
2005 |
Myeloproliferative disease
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, control mice coexpressing with TEL-PDGFRB and a DNA-binding-mutant of AE developed a nontransplantable myeloproliferative disease identical to that induced by TEL-PDGFRB alone.
|
12881486 |
2003 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
|
12036890 |
2002 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Fusion of ETV6 to MDS1/EVI1 as a result of t(3;12)(q26;p13) in myeloproliferative disorders.
|
9044825 |
1997 |
Myeloproliferative disease
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11.
|
7731705 |
1995 |